teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 146 Projects Releases Packages Wiki Activity Actions 221

auto-fix: strip 1 broken wiki links

Browse source 
Pipeline auto-fixer: removed [[ ]] brackets from links
that don't resolve to existing claims in the knowledge base.
This commit is contained in:
Teleo Agents 2026-04-14 16:52:39 +00:00
parent 126bb8cc7f
commit e680ba3f09
1 changed files with 1 additions and 1 deletions
Show stats Download patch file Download diff file Expand all files Collapse all files

2
inbox/queue/2026-03-29-circulation-cvqo-pcsk9-utilization-2015-2021.md
View file

@ -41,6 +41,6 @@ Published in *Circulation: Cardiovascular Quality and Outcomes*, 2024. Large US
**Context:** Search confirmed from multiple sources: PMC/CVQO trends study, JAHA adoption study, Amgen press release data. The pattern is consistent across data sources and time periods. **Context:** Search confirmed from multiple sources: PMC/CVQO trends study, JAHA adoption study, Amgen press release data. The pattern is consistent across data sources and time periods.
## Curator Notes ## Curator Notes
PRIMARY CONNECTION: [[Session 13 claim candidate: access-mediated pharmacological ceiling]]; GLP-1 access archives (India generic vs. US patent); OBBBA coverage loss PRIMARY CONNECTION: Session 13 claim candidate: access-mediated pharmacological ceiling; GLP-1 access archives (India generic vs. US patent); OBBBA coverage loss
WHY ARCHIVED: Quantitative anchor for access-mediated ceiling hypothesis — converts the "probably <5%" estimate from Session 13 into a documented 1–2.5% figure with specific primary source WHY ARCHIVED: Quantitative anchor for access-mediated ceiling hypothesis — converts the "probably <5%" estimate from Session 13 into a documented 1–2.5% figure with specific primary source
EXTRACTION HINT: Pair with SELECT trial CVD data and GLP-1 access barriers to build the complete "access-mediated pharmacological ceiling" claim. The pattern spans two drug generations (PCSK9 2015-2022, GLP-1 2024-present) — making it a structural pattern, not a one-time anomaly. EXTRACTION HINT: Pair with SELECT trial CVD data and GLP-1 access barriers to build the complete "access-mediated pharmacological ceiling" claim. The pattern spans two drug generations (PCSK9 2015-2022, GLP-1 2024-present) — making it a structural pattern, not a one-time anomaly.